Recurrent IDH mutations in high-grade meningioma.
作者信息
Gill Corey M, Loewenstern Joshua, Rutland John W, Arib Hanane, Francoeur Nancy, Wang Ying-Chih, Fishman Nataly, Pain Margaret, Umphlett Melissa, Kinoshita Yayoi, McBride Russell B, Bederson Joshua, Donovan Michael, Smith Melissa, Sebra Robert, Shrivastava Raj K, Fowkes Mary
机构信息
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Neuro Oncol. 2020 Jul 7;22(7):1044-1045. doi: 10.1093/neuonc/noaa065.
Abstract
摘要
相似文献
1
Recurrent IDH mutations in high-grade meningioma.高级别脑膜瘤中的复发性异柠檬酸脱氢酶（IDH）突变
Neuro Oncol. 2020 Jul 7;22(7):1044-1045. doi: 10.1093/neuonc/noaa065.
2
Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.中国人胶质母细胞瘤中异柠檬酸脱氢酶基因和端粒酶逆转录酶启动子突变的特征。
Brain Behav. 2020 Apr;10(4):e01583. doi: 10.1002/brb3.1583. Epub 2020 Mar 8.
3
Genomic profiling of anaplastic meningioma identifies recurrent genetic alterations with relevance to lower-grade meningioma.间变性脑膜瘤的基因组分析确定了与低级别脑膜瘤相关的复发性基因改变。
Neuropathol Appl Neurobiol. 2019 Feb;45(2):179-182. doi: 10.1111/nan.12487. Epub 2018 May 8.
4
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.异柠檬酸脱氢酶突变作为胶质瘤的治疗靶点。
Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.
5
Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?弥漫性胶质瘤——罕见的异柠檬酸脱氢酶纯合子点突变，它是一种致癌机制吗？
Neuropathology. 2017 Dec;37(6):582-585. doi: 10.1111/neup.12401. Epub 2017 Aug 7.
6
IDH mutations in glioma and acute myeloid leukemia.IDH 突变在胶质瘤和急性髓系白血病中的作用。
Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5.
7
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.在 IDH 突变型和 IDH 野生型弥漫性胶质瘤中，使用端粒酶启动子突变来标记具有相互临床行为的特定分子亚群。
J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.
8
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.TERT 启动子突变及其与胶质瘤中 IDH 突变的相互作用：TERT 启动子和 IDH 突变的联合将低级别胶质瘤分为不同的生存亚组——基于汇总数据的荟萃分析。
Crit Rev Oncol Hematol. 2017 Dec;120:1-9. doi: 10.1016/j.critrevonc.2017.09.013. Epub 2017 Oct 3.
9
An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.对170例胶质瘤患者进行分析并进行系统评价，以研究异柠檬酸脱氢酶-1（IDH-1）突变与术前胶质瘤相关癫痫之间的关联。
J Clin Neurosci. 2016 Sep;31:56-62. doi: 10.1016/j.jocn.2015.11.030. Epub 2016 Jul 9.
10
Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.扩散张量成像与传统磁共振成像相结合与少突胶质细胞瘤中的异柠檬酸脱氢酶1/2突变相关，但与1p/19q基因分型无关。
Eur Radiol. 2016 Jun;26(6):1705-15. doi: 10.1007/s00330-015-4025-4. Epub 2015 Sep 22.
引用本文的文献
1
Rapid diagnosis of adult-type diffuse glioma using a layered scheme.使用分层方案对成人型弥漫性胶质瘤进行快速诊断。
BMC Med. 2025 Jun 2;23(1):325. doi: 10.1186/s12916-025-04124-9.
2
mutation associated with accelerated time to recurrence for older patients with atypical meningiomas.与非典型脑膜瘤老年患者复发时间加速相关的突变。
Br J Neurosurg. 2025 Apr;39(2):173-179. doi: 10.1080/02688697.2023.2204927. Epub 2023 Apr 25.
3
Association between tumor mutations and meningioma recurrence in Grade I/II disease.I/II级疾病中肿瘤突变与脑膜瘤复发之间的关联。
Oncoscience. 2022 Dec 9;9:70-81. doi: 10.18632/oncoscience.570. eCollection 2022.
4
NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.NF2 突变与 2 级和 3 级复发性脑膜瘤的放射治疗抵抗有关。
J Neurooncol. 2023 Jan;161(2):309-316. doi: 10.1007/s11060-022-04197-z. Epub 2022 Nov 27.
5
ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.ARID1A 突变与非典型脑膜瘤的复发和较短的无进展生存期相关。
J Cancer Res Clin Oncol. 2023 Jul;149(8):5165-5172. doi: 10.1007/s00432-022-04442-y. Epub 2022 Nov 9.
6
Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.孕激素相关的世界卫生组织 II 级脑膜瘤行为-单机构对照病例系列。
Neurosurg Rev. 2022 Apr;45(2):1691-1699. doi: 10.1007/s10143-021-01708-w. Epub 2021 Nov 30.
7
SWI/SNF chromatin remodeling complex alterations in meningioma.脑膜瘤中 SWI/SNF 染色质重塑复合物的改变。
J Cancer Res Clin Oncol. 2021 Nov;147(11):3431-3440. doi: 10.1007/s00432-021-03586-7. Epub 2021 Mar 14.
8
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.高级/进展性脑膜瘤的不同基因组亚型：NF2 相关、NF2 特有和 NF2 无关。
Acta Neuropathol Commun. 2020 Oct 21;8(1):171. doi: 10.1186/s40478-020-01040-2.
9
NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.NF2 突变状态和肿瘤突变负担与脑膜瘤中的免疫细胞浸润相关。
Cancer Immunol Immunother. 2021 Jan;70(1):169-176. doi: 10.1007/s00262-020-02671-z. Epub 2020 Jul 13.
本文引用的文献
1
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.CBTRUS统计报告：2011 - 2015年美国原发性脑肿瘤及其他中枢神经系统肿瘤诊断情况
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131.
2
Treatment-associated DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.继发性胶质肉瘤发病机制中与治疗相关的DNA结合结构域错义突变
Oncotarget. 2017 Dec 20;9(2):2603-2621. doi: 10.18632/oncotarget.23517. eCollection 2018 Jan 5.
3
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
4
The 2007 WHO classification of tumours of the central nervous system.2007年世界卫生组织中枢神经系统肿瘤分类
Acta Neuropathol. 2007 Aug;114(2):97-109. doi: 10.1007/s00401-007-0243-4. Epub 2007 Jul 6.
Zotero 插件